Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology.
Clinical Trials
Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets
No Comments
Nivolumab (Opdivo) plus relatlimab demonstrated intracranial activity in patients with anti–PD-(L)1 refractory melanoma who have melanoma brain metastases,
Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma
The addition of relatlimab (Opdualag) to nivolumab (Opdivo) exhibited comparable efficacy outcomes vs ipilimumab (Yervoy) and nivolumab in patients with advanced melanoma
First Patient Dosed With CX-801 Plus Keytruda in Metastatic Melanoma
The first patient has been dosed with CX-801 in combination with Keytruda (pembrolizumab) in an ongoing phase 1 dose escalation study, which is evaluating the safety and initial clinical activity of the agent in patients with metastatic melanoma, according to a news release from CytomX Therapeutics.